For patients in Armenia who did not respond to the treatment available for multidrug-resistant tuberculosis (MDR-TB) there were simply no more treatment options before 2013. That meant a patient would end up in the street, in a palliative care center, or at home, waiting to die. But some companies allow the use of new drugs under the compassionate use program, meaning that trials have not ended but early studies show some encouraging results. Bedaquiline is one of the drugs. It is the first new drug to treat tuberculosis in 50 years.